{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:27Z","timestamp":1793036367193,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japanese Foundation for Multidisciplinary Treatment of Cancer","award":["Japanese Foundation for Multidisciplinary Treatment of Cancer"],"award-info":[{"award-number":["Japanese Foundation for Multidisciplinary Treatment of Cancer"]}],"id":[{"id":"https:\/\/ror.org\/02yjnch11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03178-w","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:50:24Z","timestamp":1789818624000},"page":"2673-2683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone"],"prefix":"10.1007","volume":"31","author":[{"given":"Takashi","family":"Fukagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9100","authenticated-orcid":false,"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiko","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Tatarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Chikazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"1","key":"3178_CR1","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A (2026) Cancer statistics, 2026. CA Cancer J Clin 76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"3178_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, Ikeda S, Suzuki T, Matsuda T (2021) Updated Trends in Cancer in Japan: Incidence in 1985\u20132015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence. J Epidemiol 31(7):426\u2013450. https:\/\/doi.org\/10.2188\/jea.JE20200416","journal-title":"J Epidemiol"},{"issue":"2","key":"3178_CR3","doi-asserted-by":"publisher","first-page":"e71556","DOI":"10.1002\/cam4.71556","volume":"15","author":"STY Yau","year":"2026","unstructured":"Yau STY, Hung CT, Leung EYM, Lee A, Yeoh EK (2026) Associations of Diabetes, Smoking, and Metabolic Factors With the Risk of Breast and Prostate Cancers: A Population-Based Retrospective Cohort Study. Cancer Med 15(2):e71556. https:\/\/doi.org\/10.1002\/cam4.71556","journal-title":"Cancer Med"},{"key":"3178_CR4","doi-asserted-by":"publisher","unstructured":"Lin RJ, Liu CL, Huang SK, Chiu AW, Wu YC, Tseng WH, Ho CH (2024) Impact of Smoking on Overall and Cancer-Specific Mortality in Prostate Cancer: Elevated Risks in Older and Early-Stage Patients-A Population-Based Study. Life (Basel) 14(10). https:\/\/doi.org\/10.3390\/life14101281","DOI":"10.3390\/life14101281"},{"key":"3178_CR5","doi-asserted-by":"publisher","first-page":"31358","DOI":"10.1038\/srep31358","volume":"6","author":"Z Liang","year":"2016","unstructured":"Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, Ji A, Zhu Y, Xu X, Zheng X, Xie L (2016) Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep 6:31358. https:\/\/doi.org\/10.1038\/srep31358","journal-title":"Sci Rep"},{"issue":"1","key":"3178_CR6","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.clgc.2018.09.016","volume":"17","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O (2019) Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies. Clin Genitourin Cancer 17(1):e104\u2013e112. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.016","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"3178_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, Investigators P (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"N Engl J Med"},{"issue":"2","key":"3178_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, Investigators C-A- (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"key":"3178_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","volume":"41","author":"K Izumi","year":"2022","unstructured":"Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A (2022) Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. Eur Urol Open Sci 41:16\u201323. https:\/\/doi.org\/10.1016\/j.euros.2022.04.016","journal-title":"Eur Urol Open Sci"},{"issue":"10","key":"3178_CR10","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/pros.24897","volume":"85","author":"T Okamura","year":"2025","unstructured":"Okamura T, Izumi K, Kurokawa S, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Tanaka N, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A (2025) Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study. Prostate 85(10):903\u2013911. https:\/\/doi.org\/10.1002\/pros.24897","journal-title":"Prostate"},{"issue":"1","key":"3178_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12885-017-3661-2","volume":"17","author":"K Izumi","year":"2017","unstructured":"Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S (2017) Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC Cancer 17(1):677. https:\/\/doi.org\/10.1186\/s12885-017-3661-2","journal-title":"BMC Cancer"},{"issue":"7","key":"3178_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working G (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148\u20131159. https:\/\/doi.org\/10.1200\/JCO.2007.12.4487","journal-title":"J Clin Oncol"},{"issue":"6","key":"3178_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/pros.70134","volume":"86","author":"T Hatayama","year":"2026","unstructured":"Hatayama T, Sekino Y, Kobayashi G, Yukihiro K, Nakano Y, Tasaka S, Nomura N, Kohada Y, Takemoto K, Naito M, Miyamoto S, Kobatake K, Kitano H, Goto K, Goriki A, Hieda K, Hinata N (2026) Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis. Prostate 86(6):689\u2013696. https:\/\/doi.org\/10.1002\/pros.70134","journal-title":"Prostate"},{"issue":"9","key":"3178_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10552-024-01883-3","volume":"35","author":"ET Ellis","year":"2024","unstructured":"Ellis ET, Fairman BJ, Stahr SD, Bensen JT, Mohler JL, Song L, Butler EN, Su LJ, Hsu PC (2024) Cigarette smoking and prostate cancer aggressiveness among African and European American men. Cancer Causes Control 35(9):1259\u20131269. https:\/\/doi.org\/10.1007\/s10552-024-01883-3","journal-title":"Cancer Causes Control"},{"issue":"1","key":"3178_CR15","doi-asserted-by":"publisher","first-page":"23119","DOI":"10.1038\/s41598-024-73197-y","volume":"14","author":"T Hayashi","year":"2024","unstructured":"Hayashi T, Miyamoto T, Iwane S, Fujitani M, Uchitani K, Koizumi Y, Hirata A, Kinoshita H, Kawabata A (2024) Opposing impact of hypertension\/diabetes following hormone therapy initiation and preexisting statins on castration resistant progression of nonmetastatic prostate cancer: a multicenter study. Sci Rep 14(1):23119. https:\/\/doi.org\/10.1038\/s41598-024-73197-y","journal-title":"Sci Rep"},{"issue":"13","key":"3178_CR16","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/pros.24554","volume":"83","author":"A Elshafei","year":"2023","unstructured":"Elshafei A, Al-Toubat M, Feibus AH, Koul K, Jazayeri SB, Lelani N, Henry V, Balaji KC (2023) Genetic mutations in smoking-associated prostate cancer. Prostate 83(13):1229\u20131237. https:\/\/doi.org\/10.1002\/pros.24554","journal-title":"Prostate"},{"issue":"7","key":"3178_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/pros.70142","volume":"86","author":"A Sharma","year":"2026","unstructured":"Sharma A, Sudan SK, Khan MA, Tahir M, Niyogi PG, Singh AP, Singh S (2026) Smoking Behavior Is Associated With an Altered Immune Landscape in Prostate Cancer: Implications for Patient Outcomes. Prostate 86(7):753\u2013762. https:\/\/doi.org\/10.1002\/pros.70142","journal-title":"Prostate"},{"issue":"9","key":"3178_CR18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/emmm.201202367","volume":"5","author":"K Izumi","year":"2013","unstructured":"Izumi K, Fang LY, Mizokami A, Namiki M, Li L, Lin WJ, Chang C (2013) Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2\/CCR2-induced STAT3 activation. EMBO Mol Med 5(9):1383\u20131401. https:\/\/doi.org\/10.1002\/emmm.201202367","journal-title":"EMBO Mol Med"},{"issue":"3","key":"3178_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"issue":"1","key":"3178_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pros.24082","volume":"81","author":"H Iwamoto","year":"2021","unstructured":"Iwamoto H, Izumi K, Shimada T, Kano H, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Kadono Y, Mizokami A (2021) Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. Prostate 81(1):72\u201380. https:\/\/doi.org\/10.1002\/pros.24082","journal-title":"Prostate"},{"issue":"12","key":"3178_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working G (2016) Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"key":"3178_CR22","doi-asserted-by":"publisher","unstructured":"Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A (2024) Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers (Basel) 16(3). https:\/\/doi.org\/10.3390\/cancers16030508","DOI":"10.3390\/cancers16030508"},{"issue":"1","key":"3178_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pros.24796","volume":"85","author":"N Tanaka","year":"2025","unstructured":"Tanaka N, Izumi K, Nakai Y, Shima T, Kato Y, Mita K, Kamiyama M, Inoue S, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Mizokami A (2025) Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa. Prostate 85(1):21\u201329. https:\/\/doi.org\/10.1002\/pros.24796","journal-title":"Prostate"},{"key":"3178_CR24","doi-asserted-by":"publisher","first-page":"175628722110433","DOI":"10.1177\/17562872211043341","volume":"13","author":"JJ Serrano Domingo","year":"2021","unstructured":"Serrano Domingo JJ, Alonso Gordoa T, Lorca Alvaro J, Molina-Cerrillo J, Barquin Garcia A, Martinez Saez O, Burgos Revilla J, Carrato A, Alvarez Rodriguez S (2021) The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Ther Adv Urol 13:17562872211043341. https:\/\/doi.org\/10.1177\/17562872211043341","journal-title":"Ther Adv Urol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03178-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03178-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:05:08Z","timestamp":1793034308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03178-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3178"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03178-w","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nobumichi Tanaka holds a position in an endowed chair supported by Nihon Medi-Physics Co.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}